Paroxetine-mediated GRK2 inhibition is a disease-modifying treatment for osteoarthritis

Area of Science:

• Biomedical research
• Orthopedics
• Pharmacology

Background:

• Osteoarthritis (OA) is a degenerative joint disease with no disease-modifying treatments.
• Pathological chondrocyte hypertrophy (CH) drives OA, but its regulators are unknown.
• G protein-coupled receptor kinase 2 (GRK2) pathway dysregulation is implicated in other diseases.

Purpose of the Study:

• To investigate the role of the GRK2-GPCR pathway in OA pathogenesis.
• To evaluate GRK2 inhibition as a therapeutic strategy for OA.
• To determine if paroxetine, an FDA-approved drug, can treat OA.

Main Methods:

• Surgical induction of OA in a mouse model.
• Genetic deletion of GRK2 in chondrocytes.
• Pharmacological inhibition of GRK2 using paroxetine.
• Assessment of cartilage degeneration and chondrocyte hypertrophy.
• Experiments with cultured human OA cartilage.

Main Results:

• Genetic GRK2 deletion and paroxetine treatment prevented CH in mice.
• Both interventions abated OA progression and promoted cartilage regeneration.
• Paroxetine mitigated CH and cartilage degradation in human OA cartilage cultures.
• Elevated GRK2 signaling drives CH in OA.

Conclusions:

• GRK2 signaling in chondrocytes is a key driver of CH in OA.
• GRK2 inhibition represents a potential disease-modifying therapy for OA.
• Paroxetine is identified as a promising therapeutic agent for OA treatment.